S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Bear market expert makes new prediction (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
Bear market expert makes new prediction (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
Bear market expert makes new prediction (Ad)
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Bear market expert makes new prediction (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
Bear market expert makes new prediction (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
Bear market expert makes new prediction (Ad)
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Bear market expert makes new prediction (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
Bear market expert makes new prediction (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
Bear market expert makes new prediction (Ad)
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Bear market expert makes new prediction (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
Bear market expert makes new prediction (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
Bear market expert makes new prediction (Ad)
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
NASDAQ:CARA

Cara Therapeutics - CARA Stock Forecast, Price & News

$4.91
+0.02 (+0.41%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$4.90
$5.06
50-Day Range
$4.89
$12.27
52-Week Range
$4.77
$13.97
Volume
824,247 shs
Average Volume
604,204 shs
Market Capitalization
$264.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

Cara Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
246.2% Upside
$17.00 Price Target
Short Interest
Healthy
12.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.39
Upright™ Environmental Score
News Sentiment
1.33mentions of Cara Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$73,938 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.61) to ($0.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.80 out of 5 stars

Medical Sector

59th out of 1,004 stocks

Pharmaceutical Preparations Industry

18th out of 489 stocks


CARA stock logo

About Cara Therapeutics (NASDAQ:CARA) Stock

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Receive CARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CARA Stock News Headlines

5 Stocks to Buy Immediately
America’s #1 stock picker issues 5 buy alerts – one of which is positioned to be the next Tesla. Just click to claim your copy. pixel
Analyst Ratings for Cara Therapeutics
Bear market expert makes new prediction
Nobody believed Larry Benedict's prediction in February 2020. The DOW plunged 3.5%, and he told CNBC, "It seems like there's much more to come." Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of last year, either. He predicted that "all the indexes will be negative for the year," with the Nasdaq leading the way. Once again, he was spot-on.
These 2 Stocks Are Plunging After Hours Monday
Cara Therapeutics
Cannabis Stock Movers For December 23, 2022
See More Headlines
Receive CARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CARA Company Calendar

Last Earnings
11/07/2021
Today
3/31/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CARA
Employees
84
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.00
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+238.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-85,470,000.00
Net Margins
-204.16%
Pretax Margin
-204.16%

Debt

Sales & Book Value

Annual Sales
$41.87 million
Book Value
$2.95 per share

Miscellaneous

Free Float
52,217,000
Market Cap
$271.32 million
Optionable
Optionable
Beta
0.99

Key Executives

  • Christopher PosnerChristopher Posner
    President, Chief Executive Officer & Director
  • Ryan D. Maynard
    Chief Financial Officer
  • Frèdèrique Menzaghi
    Chief Scientific Officer, Senior VP-R&D
  • Joana GoncalvesJoana Goncalves
    Chief Medical Officer
  • Scott M. TerrillionScott M. Terrillion
    Secretary & Chief Compliance Officer













CARA Stock - Frequently Asked Questions

Should I buy or sell Cara Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CARA shares.
View CARA analyst ratings
or view top-rated stocks.

What is Cara Therapeutics' stock price forecast for 2023?

6 brokers have issued 12 month target prices for Cara Therapeutics' shares. Their CARA share price forecasts range from $6.00 to $25.00. On average, they anticipate the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 238.0% from the stock's current price.
View analysts price targets for CARA
or view top-rated stocks among Wall Street analysts.

How have CARA shares performed in 2023?

Cara Therapeutics' stock was trading at $10.74 at the beginning of the year. Since then, CARA shares have decreased by 53.2% and is now trading at $5.03.
View the best growth stocks for 2023 here
.

Are investors shorting Cara Therapeutics?

Cara Therapeutics saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 5,140,000 shares, a decline of 6.4% from the February 28th total of 5,490,000 shares. Based on an average daily trading volume, of 588,000 shares, the short-interest ratio is currently 8.7 days. Currently, 12.2% of the shares of the stock are sold short.
View Cara Therapeutics' Short Interest
.

When is Cara Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our CARA earnings forecast
.

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics, Inc. (NASDAQ:CARA) issued its quarterly earnings results on Sunday, November, 7th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.34. The biopharmaceutical company had revenue of $20.27 million for the quarter, compared to analysts' expectations of $15.74 million. Cara Therapeutics had a negative net margin of 204.16% and a negative trailing twelve-month return on equity of 45.46%. During the same quarter in the previous year, the company posted ($0.35) earnings per share.

What other stocks do shareholders of Cara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY).

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Who are Cara Therapeutics' major shareholders?

Cara Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (1.89%), Geode Capital Management LLC (1.60%), Pinnacle Associates Ltd. (1.32%), Pinnacle Associates Ltd. (1.28%), Bank of America Corp DE (1.25%) and Morgan Stanley (0.92%). Insiders that own company stock include Christopher Posner, Derek T Chalmers, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Scott Terrillion and Thomas Charles Reilly.
View institutional ownership trends
.

How do I buy shares of Cara Therapeutics?

Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cara Therapeutics' stock price today?

One share of CARA stock can currently be purchased for approximately $5.03.

How much money does Cara Therapeutics make?

Cara Therapeutics (NASDAQ:CARA) has a market capitalization of $271.32 million and generates $41.87 million in revenue each year. The biopharmaceutical company earns $-85,470,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis.

How can I contact Cara Therapeutics?

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The official website for the company is www.caratherapeutics.com. The biopharmaceutical company can be reached via phone at (203) 406-3700, via email at janhavi.mohite@sternir.com, or via fax at 203-567-1510.

This page (NASDAQ:CARA) was last updated on 4/1/2023 by MarketBeat.com Staff